[Federal Register Volume 59, Number 179 (Friday, September 16, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-22995]


[[Page Unknown]]

[Federal Register: September 16, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

 

Prospective Grant of Co-Exclusive License: Second Generation 
Monoclonal Antibodies Having Binding Specificity to TAG-72 and Human 
Carcinomas and Methods for Employing the Same

AGENCY: National Institutes of Health, Public Health Services, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
limited field of use co-exclusive worldwide licenses to practice the 
invention embodied in U.S. Patent Applications Number 07/073,685 filed 
on July 15, 1987 and Number 07/547,336 filed on July 20, 1990, entitled 
``Second Generation Monoclonal Antibodies Having Binding Specificity to 
TAG-72 and Human Carcinomas and Methods for Employing the Same'', to 
Centocor, Inc., having a place of business in Malvern, PA, and to 
Miles, Inc., having a place of business in Tarrytown, NY. The patent 
rights in this invention have been assigned to the United States of 
America.
    The antibodies covered in this patent application have a higher 
binding affinity and specificity to a tumor associated glycoprotein 
(designated TAG-72) than previous monoclonal antibodies available 
against TAG-72. The current antibodies also exhibit binding specificity 
to more human carcinomas than the previous monoclonals, while 
maintaining essentially no specificity to normal adult human tissues.
    The prospective co-exclusive licenses will be royalty-bearing and 
will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 
404.7. The prospective co-exclusive licenses may be granted unless, 
within 60 days from the date of this published Notice, NIH receives 
written evidence and argument that establishes that the grant of the 
licenses would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    The field of use would be limited to in vitro non-
radioimmunodiagnostic assays utilizing TAG-72 antibody.

ADDRESSES: Requests for a copy of this patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Dr. Judith Plesset, Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, MD 20852-3804. Telephone: (301) 496-7735, ext 
247; Facsimile: (301) 402-0220. A signed Confidential Disclosure 
Agreement will be required to receive copies of the patent application. 
Properly filed competing applications for a license filed in response 
to this notice will be treated as objections to the contemplated 
license. Only written comments and/or application for a license which 
are received by the NIH Office of Technology Transfer on or before 
November 15, 1994 will be considered.

    Dated: August 31, 1994.
Barbara M. McGarey, J.D.,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-22995 Filed 9-15-94; 8:45 am]
BILLING CODE 4140-01-P